Next Gleevec Showdown Is Oct. 8
This article was originally published in PharmAsia News
Executive Summary
EDITOR’S PICK â€" Novartis has an Oct. 8 hearing before India’s Madras High Court to argue that the former head of the Indian Patent Office should be disqualified from considering the company’s appeal of a patent rejection for oncologic Gleevec (imatinib), according to The Economic Times of India
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)